Welcome to our dedicated page for Kala Pharmaceuticals news (Ticker: KALA), a resource for investors and traders seeking the latest updates and insights on Kala Pharmaceuticals stock.
Kala Pharmaceuticals Inc (NASDAQ: KALA) is a clinical-stage biopharmaceutical company pioneering novel therapies for severe ocular diseases through its proprietary MSC-S platform and nanoparticle drug formulations. This page provides authorized updates on KALA's clinical developments, regulatory milestones, and research advancements.
Investors and researchers will find verified press releases covering Phase 2/3 trial progress for lead candidate KPI-012 in PCED treatment, FDA designations for rare disease therapies, and peer-reviewed study publications. All content is curated to meet strict journalistic standards for accuracy in biopharmaceutical reporting.
The news archive includes updates on corneal healing therapies, retinal disorder research collaborations, intellectual property developments, and scientific conference presentations. Content is organized chronologically with clear sourcing to enable efficient tracking of the company's progress in ocular regenerative medicine.
Bookmark this page for direct access to Kala Pharmaceuticals' official announcements, including trial enrollment updates, partnership disclosures with academic institutions, and manufacturing scale-up progress. Check regularly for the latest validated information on this innovative developer of first-in-class ocular biologics.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) will participate in two virtual healthcare investor conferences in March 2021. The H.C. Wainwright Global Life Sciences Conference is scheduled for March 9-10, featuring a pre-recorded presentation available on March 9 at 7:00 am ET. The Oppenheimer 31st Annual Healthcare Conference will follow on March 16 at 3:50 pm ET with a fireside chat. Interested parties can access recordings on Kala's website under the 'Events' section.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) reported financial results for Q4 and full year 2020, emphasizing a pivotal year with FDA approval of EYSUVIS for dry eye disease. The company achieved $2.2 million in net product revenues for Q4, with $1.9 million from INVELTYS and $0.3 million from EYSUVIS. Despite increasing revenues, net loss for Q4 was $31.1 million and full year loss was $104.3 million. Kala has a strong cash position of $153.5 million as of Dec 31, 2020, allowing continued investment in pipeline programs addressing various ocular diseases.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) will announce its fourth quarter and full year 2020 financial results on February 25, 2021. A conference call will be held at 8:00 a.m. ET to discuss these results and provide a business update. Shareholders can use dial-in numbers 866-300-4091 (domestic) or 703-736-7433 (international) with conference ID 5865513. Kala is known for its innovative therapies for eye diseases, including EYSUVIS™ and INVELTYS™, and has ongoing pre-clinical development programs targeting key medical needs.
Kala Pharmaceuticals (NASDAQ:KALA) announced the grant of non-statutory stock options to two new employees totaling 16,500 shares. The options, issued on February 12, 2021, have an exercise price of $8.63 per share, equal to the stock's closing price on that date. The vesting schedule allows for 25% to vest after one year, with the remainder vesting monthly over three years, contingent on continued employment. This move aligns with NASDAQ Listing Rule 5635(c)(4) to attract new talent.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced that Express Scripts has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% to its National Preferred Formularies, effective February 5, 2021. EYSUVIS is the first therapy approved for the short-term treatment of dry eye disease symptoms. This addition is seen as a milestone to enhance patient access to treatment. EYSUVIS, approved in October 2020, utilizes proprietary AMPPLIFY Drug Delivery Technology for improved efficacy. The company plans to further increase formulary coverage in upcoming months.
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) announced the grant of non-statutory stock options to two new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan. A total of 8,000 stock options were granted on January 15, 2021, at an exercise price of $7.49 per share. The options have a ten-year term and vest over four years, with 25% vesting at the first anniversary of employment. This move complies with NASDAQ Listing Rule 5635(c)(4) and aims to incentivize new hires as they join Kala Pharmaceuticals.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has launched EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, approved for the short-term treatment of dry eye disease. It is now available in U.S. pharmacies. The company has expanded its ophthalmology sales force to 91 professionals and aims for 125 by 2021, pending COVID-19 conditions. With approximately $153.5 million in cash as of December 31, 2020, Kala expects to fund operations through 2022, leveraging EYSUVIS sales for financial stability.
Kala Pharmaceuticals (NASDAQ: KALA) will participate in two investor conferences in January 2021. Mark Iwicki, Chairman and CEO, is set to present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 9:10 a.m. ET. He will also have a pre-recorded fireside chat at the H.C. Wainwright BioConnect Conference, available on the Kala website starting January 11, 2021, at 6:00 a.m. ET. Kala focuses on innovative therapies for eye diseases, with products like EYSUVIS™ and INVELTYS®.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has granted non-statutory stock options to 46 new employees, totaling 233,500 shares, as inducement awards outside its 2017 Equity Incentive Plan. The options were issued on December 15, 2020, with an exercise price of $7.63, corresponding to the closing stock price on that date. Vesting occurs over four years, with 25% vesting on the first anniversary and the remainder monthly thereafter. This grant aligns with NASDAQ Listing Rule 5635(c)(4) and supports the firm's commitment to attract talent in the biopharmaceutical sector focused on ocular therapies.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has granted non-statutory stock options to four new employees as inducement awards outside its 2017 Equity Incentive Plan, following NASDAQ Listing Rule 5635(c)(4). A total of 34,500 stock options were granted on November 13, 2020, with an exercise price of $7.42 per share, matching the closing stock price on that date. The options vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments, contingent on continued employment.
